학술논문
Clinical evaluation of BioFire® multiplex-PCR panel for acute undifferentiated febrile illnesses in travellers: a prospective multicentre study.
Document Type
Academic Journal
Author
Camprubí-Ferrer D; ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.; Cobuccio L; Center for Primary Care and Public Health, University of Lausanne, Lausanne, Switzerland.; Van Den Broucke S; Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.; Balerdi-Sarasola L; ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.; Genton B; Center for Primary Care and Public Health, University of Lausanne, Lausanne, Switzerland.; Bottieau E; Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.; Navero-Castillejos J; Microbiology Department, Hospital Clínic Barcelona, Barcelona, Spain.; Martinez MJ; Microbiology Department, Hospital Clínic Barcelona, Barcelona, Spain.; Jay C; bioMérieux, Centre Christophe Mérieux, Parc PolyTec, Grenoble, France.; Grange A; bioMérieux, Centre Christophe Mérieux, Parc PolyTec, Grenoble, France.; Borland S; bioMérieux, Centre Christophe Mérieux, Parc PolyTec, Grenoble, France.; Vaughn M; BioFire Diagnostics, LLC, bioMérieux Company, Salt Lake City, UT, USA.; Rodriguez-Valero N; ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.; Almuedo-Riera A; ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.; D'Acremont V; Center for Primary Care and Public Health, University of Lausanne, Lausanne, Switzerland.; Subirà C; ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.; de Alba T; ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.; Cruz A; ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.; Van Esbroeck M; Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.; Smith C; BioFire Diagnostics, LLC, bioMérieux Company, Salt Lake City, UT, USA.; Hillman A; BioFire Diagnostics, LLC, bioMérieux Company, Salt Lake City, UT, USA.; Hanberg B; BioFire Diagnostics, LLC, bioMérieux Company, Salt Lake City, UT, USA.; Trauscht R; BioFire Diagnostics, LLC, bioMérieux Company, Salt Lake City, UT, USA.; Spampanato N; BioFire Diagnostics, LLC, bioMérieux Company, Salt Lake City, UT, USA.; Muñoz J; ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Source
Publisher: Oxford University Press Country of Publication: England NLM ID: 9434456 Publication Model: Print Cited Medium: Internet ISSN: 1708-8305 (Electronic) Linking ISSN: 11951982 NLM ISO Abbreviation: J Travel Med Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Identifying the causes of Acute Undifferentiated Febrile Illness (AUFI) is key to improve the management of returning travellers with fever. We evaluated a BioFire®FilmArray® prototype panel of multiplex nucleic acid amplification tests (NAAT) targeting different relevant pathogens in travellers returning with fever.
Methods: Prospective, multicentre study to evaluate a prototype panel in whole blood samples of adult international travellers presenting with AUFI in three European travel Clinics/Hospitals (November 2017-November 2019). We evaluated 15 target analytes: Plasmodium spp., Plasmodium falciparum, Plasmodium knowlesi, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, chikungunya virus, dengue virus, Zika virus, Anaplasma phagocytophilum, Borrelia spp., Leptospira spp., Orientia tsutsugamushi, Rickettsia spp. and Salmonella spp. Results were compared with composite reference standards (CRSs) for each target infection, including direct methods [smear microscopy, rapid diagnostic test (RDT), reference NAAT and blood cultures] and indirect methods (paired serology).
Findings: Among 455 travellers with AUFI, 229 target infections were diagnosed; the prototype panel detected 143 (overall sensitivity and specificity of 62.5 and 99.8%, respectively). The panel identified all Plasmodium infections (n = 82). Sensitivity for dengue (n = 71) was 92.9, 80.8 and 68.5% compared with RDT, NAAT and CRS, respectively. Compared with direct methods and CRS, respectively, the prototype panel detected 4/4 and 4/6 chikungunya, 2/2 and 4/29 Leptospira spp., 1/1 and 1/6 O. tsutsugamushi and 2/2 and 2/55 Rickettsia spp., but 0/2 and 0/10 Zika, 0/1 and 0/11 A. phagocytophylum and 0/3 Borrelia spp. diagnosed by serology and only 1/7 Salmonella spp. diagnosed by blood cultures. 77/86 (89.5%) infections not detected by the panel were diagnosed by serology.
Interpretation: The prototype panel allowed rapid and reliable diagnosis for malaria, dengue and chikungunya. Further improvements are needed to improve its sensitivity for Zika and important travel-related bacterial infections.
(© International Society of Travel Medicine 2023. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
Methods: Prospective, multicentre study to evaluate a prototype panel in whole blood samples of adult international travellers presenting with AUFI in three European travel Clinics/Hospitals (November 2017-November 2019). We evaluated 15 target analytes: Plasmodium spp., Plasmodium falciparum, Plasmodium knowlesi, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, chikungunya virus, dengue virus, Zika virus, Anaplasma phagocytophilum, Borrelia spp., Leptospira spp., Orientia tsutsugamushi, Rickettsia spp. and Salmonella spp. Results were compared with composite reference standards (CRSs) for each target infection, including direct methods [smear microscopy, rapid diagnostic test (RDT), reference NAAT and blood cultures] and indirect methods (paired serology).
Findings: Among 455 travellers with AUFI, 229 target infections were diagnosed; the prototype panel detected 143 (overall sensitivity and specificity of 62.5 and 99.8%, respectively). The panel identified all Plasmodium infections (n = 82). Sensitivity for dengue (n = 71) was 92.9, 80.8 and 68.5% compared with RDT, NAAT and CRS, respectively. Compared with direct methods and CRS, respectively, the prototype panel detected 4/4 and 4/6 chikungunya, 2/2 and 4/29 Leptospira spp., 1/1 and 1/6 O. tsutsugamushi and 2/2 and 2/55 Rickettsia spp., but 0/2 and 0/10 Zika, 0/1 and 0/11 A. phagocytophylum and 0/3 Borrelia spp. diagnosed by serology and only 1/7 Salmonella spp. diagnosed by blood cultures. 77/86 (89.5%) infections not detected by the panel were diagnosed by serology.
Interpretation: The prototype panel allowed rapid and reliable diagnosis for malaria, dengue and chikungunya. Further improvements are needed to improve its sensitivity for Zika and important travel-related bacterial infections.
(© International Society of Travel Medicine 2023. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)